Compare EH & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EH | IRWD |
|---|---|---|
| Founded | 2014 | 1998 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 745.8M | 663.6M |
| IPO Year | 2019 | 2009 |
| Metric | EH | IRWD |
|---|---|---|
| Price | $9.88 | $4.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $22.47 | $7.67 |
| AVG Volume (30 Days) | 505.1K | ★ 1.7M |
| Earning Date | 05-26-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1400.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $298,276,000.00 |
| Revenue This Year | $33.23 | $57.95 |
| Revenue Next Year | $73.83 | $4.39 |
| P/E Ratio | ★ N/A | $27.03 |
| Revenue Growth | N/A | ★ 8.88 |
| 52 Week Low | $9.06 | $0.55 |
| 52 Week High | $20.44 | $5.78 |
| Indicator | EH | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 59.62 |
| Support Level | $9.06 | $3.07 |
| Resistance Level | $11.94 | $4.50 |
| Average True Range (ATR) | 0.41 | 0.23 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 4.41 | 83.03 |
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company. It focuses on making safe, autonomous, eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with unmanned aerial vehicle (UAV) systems and solutions: air mobility (including passenger transportation and logistics), smart city management, and aerial media solutions. EHang's EH216-S has received a production certificate and standard airworthiness certificate for passenger-carrying pilotless eVTOL aircraft issued by the Civil Aviation Administration of China. The group continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.